ERBB2 and breast cancer: Some studies clearly show that even in the absence of trastuzumab, women with HER2-positive breast cancer have an increased propensity to develop CNS metastases compared with women with HER2-negative disease (Pestalozzi and Brignoli, 2000; Pestalozzi et al, 2006).